Study on Newborn Babies With a Yellow Skin Color (Neonatal Jaundice Study)
NCT02361788 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1710
Last updated 2023-01-17
Summary
Background: Neonatal hyperbilirubinemia is the most common reason for admission in the neonatal period (first month of life) worldwide and at SMRU. The skin of the newborn baby becomes jaundiced, which is caused by a high level of bilirubin in the blood. In some neonates the level of bilirubin increases to a level that can cause braindamage or even death. There are different causes known that can lead to higher levels of bilirubin, for example G6PD deficiency and prematurity. In case of neonatal hyperbilirubinemia the neonate needs to be treated with phototherapy (blue light therapy). If there is prolonged jaundice (≥ 21 days), further investigations needs to be done.
Objectives:
Primary objective:
To determine the etiology of neonatal hyperbilirubinemia in neonates with a gestational age of ≥ 28 weeks from the refugee and migrant population, on the Thai-Myanmar border.
Secondary objective:
* Establishing the incidence of neonatal hyperbilirubinemia
* Determine the risk factors for the development of neonatal hyperbilirubinemia
* Determine the incidence of prolonged neonatal jaundice
* Determine the neurodevelopmental outcome, at the age of 6 and 12 months
* Determine the body composition, using air-displacement plethysmography, at birth, 1, 2 and 3 months of age
* Determine the incidence of anaemia and illness episodes during the first year of life
* Determine the incidence of helminthic infection at the age of one year
* Assess the knowledge level and misbeliefs on neonatal hyperbilirubinemia among the mothers and SMRU health care staff
Research design: The study will conduct an exhaustive prospective descriptive study, all eligible newborns will be enrolled after obtaining the informed consent from their mothers. During pregnancy and delivery we will collect clinical data about the mother. At birth we will take umbilical cord blood (9 ml) to test for different causes of neonatal hyperbilirubinemia. In the first week of life we plan 4 moments to measure the bilirubin and hematocrit level (0.05 ml), weight and ask questions about feeding and other practices. Based on the bilirubin results we will determine whether the neonate needs phototherapy. After the first week we weekly follow-up will be conducted and in case of visible jaundice we will measure the bilirubin level. If the neonate is still jaundiced after the age of 21 days we will further investigate the cause. In the infant period, until the age of one year, we plan to have monthly follow-up to assess the health and growth of the child and at the age of 3, 6 and 12 months we will do a neurodevelopmental test.
An improved understanding of the pathological processes contributing to the development of neonatal hyperbilirubinemia is needed in order to to identify neonates at risk and develop improved management.
Conditions
- Neonatal Hyperbilirubinemia
Sponsors & Collaborators
-
University of Oxford
lead OTHER
Principal Investigators
-
François Nosten, Prof. · Shoklo Malaria Research Unit
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-01-28
- Primary Completion
- 2016-06-12
- Completion
- 2019-05-18
Countries
- Thailand
Study Locations
More Related Trials
-
Value of Transcutaneous Bilirubin Devices
NCT06232174 ·Status: NOT_YET_RECRUITING
-
Prediction of Jaundice in Term Infants
NCT01203410 ·Status: COMPLETED
-
TCB Self-Monitoring in Healthy Term and Near-Term Neonates
NCT06645158 ·Status: COMPLETED
-
NeoSCB App for Screening Jaundice in Newborns
NCT06963450 ·Status: RECRUITING
-
Outcomes of Neonatal Resuscitation
NCT02840682 ·Status: COMPLETED
-
Unbound Bilirubin Levels in Healthy Term and Late Preterm Infants
NCT03237715 ·Status: UNKNOWN
-
Development of TcB Nomogram to Identify Neonatal Hyperbilirubinemia in Term and Late-preterm Infants
NCT01763632 ·Status: COMPLETED
-
Transcutaneous Bilirubinometry in Healthy Term and Near-Term Neonates
NCT00653874 ·Status: COMPLETED ·Phase: PHASE3
-
Validity of Transcutaneous Bilirubin Monitoring in Preterm Infants
NCT03195998 ·Status: COMPLETED
-
Bilirubin Binding Capacity to Assess Bilirubin Load in Preterm Infants
NCT02691156 ·Status: COMPLETED
-
Transcutaneous Bilirubinometry in Neonates
NCT01422655 ·Status: COMPLETED
-
Prediction and Evaluation by ETCOc of Neonatal Hyperbilirubinemia Cohort
NCT06341582 ·Status: RECRUITING
-
Evaluation of Bilirubin Measurements in Newborns From Smartphone Digital Images in a Population in Botswana
NCT06372093 ·Status: COMPLETED ·Phase: NA
-
Evaluation of a Smartphone-based Screening Tool (Picterus JP) for Neonatal Jaundice (Chicago)
NCT05521607 ·Status: RECRUITING ·Phase: NA
-
Evaluation of a Smartphone-based Screening Tool for Neonatal Jaundice in a Ugandan Population
NCT05365399 ·Status: TERMINATED ·Phase: NA
-
Efficacy Study of the Draeger Jaundice Meter (JM-105) in Neonates of ≥ 24 Weeks of Gestational Age
NCT02774434 ·Status: COMPLETED ·Phase: NA
-
Molecular Signature Children
NCT03104673 ·Status: COMPLETED
-
Assessment of Neonatal Hyperbilirubinemia by NeoprediX B.1 Algorithm
NCT05121311 ·Status: COMPLETED
-
Transcutaneous Screening for Risk of Severe Hyperbilirubinemia in South African Newborns
NCT02613676 ·Status: COMPLETED ·Phase: NA
-
A mHealth Application as a Screening Tool for Neonatal Jaundice in Filipino Neonates
NCT05616845 ·Status: COMPLETED ·Phase: NA
-
Evaluation of a Smartphone-based Screening Tool (Picterus Jaundice Pro) for Neonatal Jaundice in Dark Skin Newborns
NCT05650463 ·Status: COMPLETED ·Phase: NA
-
Intelligent Follow-up of Neonatal Jaundice Based on Early Indicators and Internet Communications
NCT05365984 ·Status: UNKNOWN ·Phase: NA
-
Implementation of a Transcutaneous Bilirubinometer
NCT01622699 ·Status: COMPLETED ·Phase: NA
-
Multi-center Clinical Study on Neonatal Hyperbilirubinemia
NCT03824990 ·Status: COMPLETED ·Phase: NA
-
Evaluation of a Smartphone Based Screening Tool for Neonatal Jaundice in Surabaya, Indonesia
NCT05623566 ·Status: TERMINATED ·Phase: NA